University of Limerick Institutional Repository

Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland

DSpace Repository

Show simple item record

dc.contributor.author Linnane, Barry
dc.contributor.author Kiernan, Miranda G.
dc.contributor.author O'Connell, Nuala H.
dc.contributor.author Kearse, Linda
dc.contributor.author Dunne, Colum P.
dc.date.accessioned 2016-01-20T15:02:06Z
dc.date.available 2016-01-20T15:02:06Z
dc.date.issued 2015
dc.identifier.uri http://hdl.handle.net/10344/4836
dc.description peer-reviewed en_US
dc.description.abstract Rationale: There is limited evidence supporting the routine use of palivizumab in paediatric cystic fibrosis (CF) patients to reduce respiratory syncytial virus (RSV) infection and related hospitalisation. Despite this, anti-RSV prophylaxis is increasingly common. This is the first report from Ireland regarding palivizumab outcomes for children with CF, under 2 years old, despite the greatest prevalence of CF globally. Methods: An audit was performed at a tertiary hospital in Ireland’s mid-West to document all children with CF, <24 months old, who received palivizumab over a five year period and comparision made with all eligible children for the prior five year period who had not received the product (also CF patients). Palivizumab was administered to both cohorts in their first year of life. Hospitalisation rates were compared using Fisher’s exact test. Incidence of RSV and Pseudomonas aeruginosa infection was recorded. Results: A total of 19 patients who received palivizumab were included in the study; comparision was made with a retrospective control group of 30 patients. Prophylactic palivizumab did not prevent hospitalisation for 10/19 patients, 3 of whom were affected by RSV. This was significantly greater than in the control group, where no hospitalisations were recorded (p < 0.0001). P. aeruginosa was isolated in one case from the study cohort, while no P. aeruginosa was detected in the control group. Conclusions: This study, the first of its kind from Ireland where CF prevalence is highest, does not provide unequivocal support for prophylactic use of palivizumab in CF patients under 2 years. Despite being derived from a small sample size, based on these data and complementary clinical observation, we have discontinued such prophylaxis. However, should reported incidence of RSV-related hospitalisation increase, there is scientific plausibility for appropriately powered, randomised, controlled trials of palivizumab. en_US
dc.language.iso eng en_US
dc.publisher BioMed Central en_US
dc.relation.ispartofseries Multidisciplinary Respiratory Medicine;10:32
dc.subject paediatric en_US
dc.subject cystic fibrosis en_US
dc.subject RSV en_US
dc.subject efficacy en_US
dc.title Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland en_US
dc.type info:eu-repo/semantics/contributionToPeriodical en_US
dc.type.supercollection all_ul_research en_US
dc.type.supercollection ul_published_reviewed en_US
dc.identifier.doi 10.1186/s40248-015-0029-9
dc.rights.accessrights info:eu-repo/semantics/openAccess en_US
dc.internal.rssid 1595191


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ULIR


Browse

My Account

Statistics